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CONCLUSIONS
• A clear relationship is observed between improvements in pain and improvements in patient-
reported daily function, sleep, anxiety, and depression in patients with chronic posttraumatic
neuropathic pain
• To our knowledge, this is the first study that demonstrates this set of relationships in patients
with posttraumatic peripheral neuropathic pain
• Specifically, these results provide a direct quantitative relationship between an incremental
change in pain severity and the expected magnitude of change of a given PRO for an
individual patient with posttraumatic peripheral neuropathic pain
• The results of this analysis may be helpful in setting patient expectation for the benefit of
analgesic treatment
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• Chronic pain impacts many aspects of patients’ lives, including daily functioning, sleep,
and mood1
• Numerous patient-reported outcome (PRO) measures have been developed to assess pain
severity and other outcomes in clinical trials of chronic pain
• Assessment of daily function and mood is recommended in clinical trials of chronic pain2; while
assessment of sleep is not specifically recommended, it is justified by strong evidence for an
adverse effect of pain on sleep3
• Understanding the relationship between changes in pain severity and impact on daily function,
mood, and sleep disturbance may help inform treatment decisions and set patient expectations
for impact of analgesic therapy
• To evaluate the relationship between changes in pain severity and changes in patient-reported
sleep disturbance, pain interference with daily function, and anxiety and depression in patients
with posttraumatic peripheral neuropathic pain
Study Design
• This is a secondary analysis of data derived from a randomized, double-blind, placebo-
controlled, 8-week clinical study of flexible-dose pregabalin in patients with posttraumatic
peripheral neuropathic pain4
Patients
• All patients with data from the clinical trial were included in this analysis regardless of treatment
allocation or effects
Assessments
• Average weekly score on the numeric rating scale (NRS; 0 = no pain to 10 = worst possible
pain) recorded daily by patients
• Pain Severity Index (average of the 4 scores from worst pain, least pain, average pain, and pain
now) and Pain Interference Index (composite of 7 interference items rated 0 [does not interfere]
to 10 [completely interferes]) from the modified Brief Pain Inventory5
• Hospital Anxiety and Depression Scale anxiety (HADS-A) and depression (HADS-D) subscales
based on 1-week recall6
• Medical Outcomes Study–Sleep Scale (MOS-SS) 9-item Sleep Problems Index and 4-item
sleep disturbance subscale based on 1-week recall7
• Daily Sleep Interference Scale (0 = no interference to 10 = completely interferes) based on
24-hour recall
Analyses
• Changes from baseline to end of treatment at week 8 in PRO scores were evaluated as a
function of the change in pain NRS score over the same period
• Linear regression models were used to evaluate the relationship between change in pain and PROs
• Mean changes in PROs were estimated for a 2-point improvement in pain severity, a clinically
meaningful improvement8
• Four sensitivity analyses were performed
– Patients with ≥30% pain response
– Patients with ≥50% pain response
– Patients treated with pregabalin
– Patients treated with placebo
• Analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, North Carolina, USA)
• P<0.05 was considered statistically significant
METHODS
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• Main study results have been reported elsewhere4
• Patients (N=254) had a mean age of 51.7 years and 50.8% were female (Table 1)
RESULTS
• A 2-point decrease in pain was associated with an estimated 1.5-point decrease in HADS-A
and a 1.2-point decrease in HADS-D (Figure 3)
Table 1. Patient Demographic and Clinical Characteristics
Placebo (n=127) Pregabalin (n=127)
Women, n (%) 52 (40.9) 77 (60.6)
Mean age (SD), y 51 (13) 52 (14)
Age 65–80 years, n (%) 25 (19.7) 29 (22.8)
White, n (%) 120 (94.5) 124 (97.6)
Mean weight (SD), kg 81 (17) 78 (15)
Mean duration of neuropathic pain (range) 4.4 (0.2–29.0) 4.3 (0.3–26.0)
Primary neuropathic pain diagnosis,a n (%)
Trauma 59 (46.5) 62 (48.8)
Surgical 41 (32.3) 44 (34.6)
Amputation 6 (4.7) 3 (2.4)
Nerve injury 12 (9.4) 8 (6.3)
Other 9 (7.1) 10 (7.9)
Concomitant pain medications,b n (%) 101 (79.5) 102 (80.3)
NSAIDs/COX-2 46 (36.2) 57 (44.9)
TCAs 39 (30.7) 41 (32.3)
SNRI 7 (5.5) 2 (1.6)
Opioids 15 (11.8) 20 (15.8)
Tramadol 41 (32.3) 42 (33.1)
Anticonvulsantsc 46 (36.2) 41 (32.3)
SD, standard deviation; NSAIDs, nonsteroidal anti-inflammatory drugs; COX-2, cyclooxygenase 2; TCAs, tricyclic antidepressants; 
SNRI, serotonin-norepinephrine reuptake inhibitor
a As reported by investigator
b Medications may not have been specifically prescribed for neuropathic pain
c Antiepileptic drugs other than gabapentin were allowed
• Linear relationships were observed between change in patient-reported sleep disruption (Figure 1),
pain interference on daily function (Figure 2), and anxiety and depression symptoms (Figure 3)
as a function of changes in pain severity on the NRS 
• The derived plots can be interpreted as showing, at the individual patient level, the mean
change in PRO score (y axis) that can be expected with the various incremental changes in pain
severity (x axis)
• For example, a 2-point decrease in pain corresponded to an estimated 7.6-point decrease
(improvement) in the MOS-SS 9-Item Sleep Problems Index, 11.9-point decrease in MOS-SS
sleep disturbance, and 1.6-point decrease in sleep interference (Figure 1)
• A 2-point decrease in pain was associated with an estimated 1.5-point decrease in pain
interference on daily function (Figure 2)
Figure 1. Relationship Between Change in Pain Severity and Sleep Disruption 
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Figure 2. Relationship Between Change in Pain Severity and Change in Pain Interference on
Daily Function 
N=254
P<0.001 for the overall relationship
mBPI-sf, modified Brief Pain Inventory short-form; CI, confidence interval
N=254
P<0.001 for the overall relationship in each figure
MOS-SS, Medical Outcomes Study–Sleep Scale; CI, confidence interval
• Significant associations between change in pain severity and change in each PRO were
observed (Figures 1–3; P<0.001)
• The mean improvements in sleep, pain interference on daily function, and mood outcome scores
that correspond to a 2-point improvement in pain severity score (a clinically important
improvement) are shown in Table 2
• In general, these sensitivity analyses tended to support the results of the main analysis of the
total sample, with some exceptions; for example, 50% responders on the Pain Interference
Index scale and the placebo group for HADS-D subscale and for the MOS-SS 9-item Sleep
Problems Index (Table 2)
Figure 3. Relationship Between Change in Pain Severity and Mood
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A. Anxiety B. Depression
N=254
P<0.001 for the overall relationship for each figure
HADS-A, Hospital Anxiety and Depression Scale–anxiety subscale; CI, confidence interval; HADS-D, Hospital Anxiety and Depression 
Scale–depression subscale
• For some of the PROs, there was a change in score even with no change in pain severity. For
example, individuals with no change in pain severity still showed almost a 4.3-point improvement
on the MOS-SS sleep disturbance subscale
• This can be taken to suggest that there may exist effects of treatment that are independent of
the effects on pain, which, in this case, can be specific effects on sleep
• Further support for this comes from a sensitivity analyses, for which pregabalin-treated patients
with no change in pain improved (decreased) by 7.50 points on MOS-SS sleep disturbance
subscale, whereas placebo-treated patients with no change in pain improved only by 1.35 points
on sleep disturbance subscale
Table 2. Mean (95% CI) Improvement in PROs That Corresponded to a 2-Point Improvement
in Pain
MOS-SS 9-
Item Sleep Pain 
MOS-SS Sleep Problems Sleep Interference
Disturbance Index Interference HADS-A HADS-D Index
All subjects (N=254) –11.87 –7.59 –1.64 –1.52 –1.23 –1.48 
(–14.83, –8.91) (–9.91, –5.27) (–1.86, –1.43) (–1.97, –1.07) (–1.58, –0.88) (–1.72, –1.25)
Subgroups
≥30% responders –11.57 –7.41 –1.54 –1.57 –1.39 –1.68 
(n=82)a (–19.17, –3.98) (–13.31, –1.50) (–2.05, –1.03) (–2.61, –0.53) (–2.13, –0.65) (–2.22, –1.14)
≥50% responders –13.12 –8.37 –1.70 –2.04 –1.25 –2.21
(n=48)a (–25.04, –1.19) (–18.07, –1.32) (–2.7, –0.70) (–3.88, –0.21) (–2.5, 0) (–3.13,–1.28)
Pregabalin-treated –15.79 –9.85 –1.67 –1.64 –1.56 –1.71 
patients (n=127) (19.76, –11.83) (–13.14, –6.57) (–1.96, –1.38) (–2.25, –1.03) (–2.00, –1.12) (–2.05, –1.38)
Placebo-treated –7.09 –4.93 –1.62 –1.41 –0.83 –1.18 
patients (n=127) (–11.51, –2.68) (–8.22, –1.65) (–1.95, –1.29) (–2.09, –0.74) (–1.39, –0.27) (–1.51, –0.85)
CI, confidence interval; PRO, patient-reported outcome; MOS-SS, Medical Outcomes Study–Sleep Scale; HADS-A, Hospital Anxiety and 
Depression Scale–anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale–depression subscale
a ≥30% and ≥50% responders are those patients who achieved at least a 30% and 50% reduction in pain, respectively, in the clinical trial on 
which this analysis was based
Reductions in scores on pain and other PROs represent improvements
